KLRS Q4 2022 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena

KLRSKalaris Therapeutics Inc

$187M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$1M

Operating Income

-$40M

Net Income

-$38M

EPS (Diluted)

$-9.42

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$277M

Total Liabilities

$53M

Stockholders' Equity

$225M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$1M	-$554,000	-97.5%
Operating Income	-$40M	-$56M	+27.5%
Net Income	-$38M	-$58M	+34.2%